Immuno-Oncology: Emerging Targets and Therapeutics


The paradigm of immuno-oncology: figuring out and then circumventing how cancer cells evade the immune system, has been validated by a few high-impact therapeutic successes in the past few years and has thus spurred a flurry of more drug discovery and development in the field. However much of the current pharmaceutical activity is focused on a few cell surface drug targets and their inhibition by biologics-based therapies. CHI’s Inaugural Immuno-Oncology: Emerging Targets and Therapeutics conference will cover newer cell surface targets in the IO field that are being investigated for modulation by biologics as well as by other modalities, especially small molecules that have the potential to be oral-based medicines. We will also cover drug targets that are intracellular, thus only accessible to small molecules or newer, non-biologic modalities. Please join us to stay abreast of this rapidly progressing field.

Preliminary Agenda

Re-activating the Innate Immune System Against Cancer

Using Synthetic Biology to Target Innate Immunity in the Tumor Microenvironment
Jose M. Lora, PhD, Vice President, Research, Synlogic, Inc.

Discovery of STING Agonist with Systemic Anti-Tumor Response
Scott Pesiridis, PhD, Associate Fellow, Scientific Leader—Discovery Biology, GSK

Characterization of Novel STING Ligands
Gottfried Schroeder, PhD, Senior Scientist, Department of Pharmacology, Merck Research Labs Boston

Cyclic Dinucleotides that Self-Assemble into Nanostructures as Potent STING Agonists for Immuno-Therapy of Cancer
Radhakrishnan P. Iyer, PhD, CSO, Spring Bank Pharmaceuticals

Targeting Immuno-Metabolism to Remodel the Tumor Microenvironment (TME)

Targeting the Adenosine Immunosuppressive Pathway
Daniela Cipolletta, PhD, Investigator III, Exploratory ImmunoOncology, Novartis

Antagonists of the Adenosine 2a Receptor (A2AR) to Reverse Tumor Suppression in the TME
Alwin Schuller, PhD, Senior Principal Scientist/Team Lead, Oncology, IMED Biotech Unit, Astra Zeneca

Dual Inhibitors of CD73 and A2AR for Effective Suppression of the Adenosine Signaling Pathway
Murali Ramachandra, PhD, CSO, Aurigene Discovery Technologies Limited

Targeting the Dopamine Receptor for Immuno-Oncology
Joshua Allen, PhD, Senior Vice President, Research & Development, Oncoceutics

* The program is subject to change without notice, due to unforeseen reason.

Choose your language
Traditional Chinese
Simplified Chinese

Update History
Event Information updated

Premier Sponsors

Ablexis Alivamab_stacked



OmniAb Ligand_Pharmaceuticals